ESR1 and breast cancer: Given ER is the most important molecular target in BC targeted therapy, the use of selective estrogen receptor modulators (SERMs) which block the effects of endogenous estrogen in breast tissues thereby competing with estrogen for ER binding, has been acknowledged as one of the most effective strategies [20].